OMOMHealthcare · Medical Devices

OM Stock Forecast: Outset Medical, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.81
−3.44% on the day

The 3 Wall Street analysts covering Outset Medical, Inc. hold a median 12-month price target of $7 — +149.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 52 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$54.9M
Ticker Nerd rank
52/ 100
Median analyst target
$7.00
Analysts covering
3
Revenue$31.6M+0.7% y/y
Operating income−$15.7M
Net income−$18.0M
Free cash flow−$9.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−24.7%
1M
−33.4%
YTD
−24.3%
1Y
−36.7%
From 52W high
−50.5%
From 52W low
0.0%
$2.81
$5.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Outset Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
52/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Revisions
81
Growth
61
Quality
60
Value
32
Volatility
18
Issuance
17
Momentum
8

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26OMHigh $10.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$6.00
Low
$7.00
Median
$10.00
High

The green dot is the last close — the median target sits +149.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Feb 2026BTIGMaintainsBuy$17 → $15
7 Jan 2026StifelMaintainsBuy—
16 Dec 2025BTIGReiteratesBuy—
11 Nov 2025BTIGMaintainsBuy—
11 Nov 2025RBC CapitalMaintainsSector Perform—
11 Nov 2025StifelMaintainsBuy—
19 Aug 2025RBC CapitalReiteratesSector Perform—
7 Aug 2025RBC CapitalMaintainsSector Perform—
21 May 2025RBC CapitalMaintainsSector Perform—
8 May 2025RBC CapitalMaintainsSector Perform—
7 Jan 2025RBC CapitalReiteratesSector Perform—
8 Aug 2024RBC CapitalDowngradeSector Perform—
8 Aug 2024TD CowenMaintainsBuy—
21 June 2024RBC CapitalUpgradeOutperform—
8 Apr 2024BTIGInitiatesBuy—
12 Jan 2024RBC CapitalDowngradeSector Perform—
4 Dec 2023Morgan StanleyMaintainsEqual-Weight—
14 Nov 2023Morgan StanleyMaintainsEqual-Weight—
13 Oct 2023B of A SecuritiesDowngradeUnderperform—
13 Oct 2023RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OM.

Market Radar

This page is one stock. Monday covers all of them.

OM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Outset Medical, Inc. returned −36.7% against +6.9% for the S&P 500, dividends included.

OM vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26OMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.5×

Cheaper than 80% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
42.0%

Higher than 52% of US stocks

Operating margin
−51.2%

Higher than 18% of US stocks

Net margin
−58.3%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−63.0%

Higher than 19% of US stocks

Return on assets
−15.4%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Outset Medical, Inc. has a market value of $54.9M and an enterprise value of $23.1M.

  • Revenue in the twelve months to 30 June 2026: $117.8M. The latest quarter grew 0.7% year on year.

  • Net income over the same four quarters: −$74.3M, a −63.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$4.09.

  • Free cash flow in the twelve months to 30 June 2026: −$38.9M.

  • Shares outstanding: 18.8M.

  • Outset Medical, Inc. employs 310 people — $380K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

OM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
OMOutset Medical, Inc.$54.9M52
COCHEnvoy Medical, Inc.$51.9M57
LNSRLENSAR, Inc.$54.8M58
MBOTMicrobot Medical, Inc.$45.7M15
HYPRHyperfine, Inc.$58.0M42
ELUTElutia, Inc.$39.9M30
ECORelectroCore, Inc.$39.9M75

Take a look at OM’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Outset Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OM

What is the OM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Outset Medical, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OM stock a buy right now?

Of the 3 analysts covering Outset Medical, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outset Medical, Inc. 52 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OM?

As at 21 Nov 2026, Outset Medical, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will OM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +149.1% from the last close, and Ticker Nerd's factor model ranks Outset Medical, Inc. 52 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OM stock forecast for 2030?

No analyst covering Outset Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.

How has OM stock performed over the past year?

Outset Medical, Inc. returned -36.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Outset Medical, Inc. do?

Outset Medical, Inc. is a medical technology company focused on dialysis care. Its core product, the Tablo Hemodialysis System, is designed to simplify hemodialysis by combining integrated water purification, on-demand dialysate production, software, and connectivity in a compact platform.

Company

About Outset Medical, Inc.

Outset Medical, Inc. is a medical technology company focused on dialysis care. Its core product, the Tablo Hemodialysis System, is designed to simplify hemodialysis by combining integrated water purification, on-demand dialysate production, software, and connectivity in a compact platform. The company also provides related consumables and a data ecosystem that includes tools for healthcare providers, patients, and internal analytics. Outset Medical serves hospitals, dialysis clinics, and home-care settings, supporting dialysis delivery across the continuum of care. The company’s products are positioned to help healthcare providers manage dialysis programs with a more streamlined and technology-enabled workflow. Headquartered in San Jose, California, Outset Medical operates in the renal care and medical equipment markets, where it offers a specialized solution for patients and providers involved in kidney replacement therapy.

CEO Ms. Leslie L. Trigg · 310 employees · United States · https://www.outsetmedical.com